BSXBoston Scientific
Price
-56%1YEnd-of-day closes, not the intraday tick.
A rare clean sweep: double-check what the checks can't see
Quality strong, no red flags, undemanding price, growing in the filings, the market undecided.
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties. Our mission is to transform lives through innovative medical solutions that improve the health of patients around the world. As a medical technology leader for more than 45 years, we have advanced the practice of less-invasive medicine by helping physicians and other medical professionals diagnose and treat a wide range of diseases and medical conditions and improve patients’ quality of life by providing alternatives to surgery and other medical procedures that are typically traumatic to the body.
In the company’s own words · 10-K filed Feb 17, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Boston Scientific (BSX) reported revenue of $5.44B in Q2 2026 (quarter ended Jun 30, 2026), up 7.5% from the same quarter a year earlier. That came with a gross margin of 71% and net income of $905M (17% of revenue). For the full year FY2025, revenue was $20.1B (+20% year on year) and net income $2.89B. Its largest product in Q2 2026 was Electrophysiology EP at $606M, 18% of the disclosed total, just ahead of Interventional Cardiology Therapies at 17%. The next results filing is expected around Oct 21, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 7, 2026Chief Operating Officer On October 7, 2026, Boston Scientific Corporation (the “Company”) announced that Joe Fitzgerald, who currently serves as Executive Vice President and Group President, Cardiovascular, has been promoted to Executive Vice President and Chief Operating Officer of the Company, effective as of …Director or officer change · Form 8-K
- Sep 23, 2026On September 21, 2026, Arthur C. Butcher informed Boston Scientific Corporation (the “Company”) that he has decided to retire from his role as Executive Vice President and Group President, MedSurg and Asia Pacific effective as of January 1, 2027.Director or officer change · Form 8-K
- Sep 8, 2026As previously disclosed in a Current Report on Form 8-K filed on August 26, 2026 with the Securities and Exchange Commission, on August 25, 2026, Boston Scientific Corporation (the “Company”) identified a cybersecurity incident that affected certain of its information technology systems and resulted in a global …Material cybersecurity incident · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2026 · $3.43BThe company’s own SEC segment disclosure.
- Electrophysiology EP$606.0M18%
- Interventional Cardiology Therapies$586.0M17%
- Global Urology and Pelvic Health Reporting Unit$503.0M15%
- Global Endoscopy Endo Reporting Unit$491.0M14%
- Watchman$459.0M13%
- Cardiac Rhythm Management$349.0M10%
- Other (2)$432.0M13%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Medical Devices
The closest names by size in the same industry